Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Mol Cell Cardiol. 2015 May 22;85:104–116. doi: 10.1016/j.yjmcc.2015.05.012

Figure 6. Impact of MnTBAP on insulin-stimulated cardiomyocyte glucose uptake and myocardial glucose utilization in 13 and 24-week-old UCP-DTA mice.

Figure 6

A. Insulin-stimulated 2-deoxy-3H-glucose uptake in isolated cardiomyocytes from 13 week-old and control hearts treated with saline or MnTBAP (n=4–5). B–D. Glycolysis, glucose oxidation, and cardiac power measured in isolated working heart preparations with or without 1nM insulin in 13 week-old UCP-DTA and control mice (n=5–7). E. Insulin-stimulated 2-deoxy-3H-glucose uptake in isolated cardiomyocytes from 24 week-old UCP-DTA and control hearts treated with saline or MnTBAP (n=5–7). F–H. Glycolysis, glucose oxidation, and cardiac power measured in isolated working heart preparations with or without 1nM insulin in 24 week-old UCP-DTA or control mice (n=5–7). I–K. Glycolysis, glucose oxidation, and cardiac power in db/db hearts measured in isolated working heart preparations without insulin (n=3–4). *p<0.05 vs. other genotypes in the same treatment group; # p<0.05 for insulin- stimulated vs. basal state for same genotype.

Inline graphic Saline-treated control wildtype (WT) mice, Inline graphic MnTBAP-treated WT mice, Inline graphic UCP-DTA or db/db mice treated with saline, Inline graphic UCP-DTA or db/db mice, treated with MnTBAP. Dw=dry weight.